Real-World Use of COMT Inhibitors in the Management of Patients with Parkinson's Disease in Spain Who Present Early Motor Fluctuations: Interim Results from the REONPARK Study.

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

ObjectiveWe aimed to analyze the real-world use of COMT inhibitors associated with levodopa in patients with Parkinson's disease (PD) who present early fluctuations and to explore whether early COMT inhibition optimizes treatment outcomes.MethodsREONPARK is an ongoing 2-year prospective observational study. We included patients diagnosed with PD who presented signs of end-of-dose motor fluctuations for ResultsSeventy patients were analyzed (mean levodopa dose at inclusion 484.8 mg; duration of motor fluctuations 0.6 years). In all cases, COMT inhibition was initiated with opicapone, and 81% maintained a stable levodopa dose at 3 months. After 3 months of treatment with opicapone, 73.5% and 62.8% of patients improved on CGI-C and PGI-C, respectively. MDS-UPDRS scores improved significantly with a mean change from baseline of -3.3 ± 7.7 (p p ConclusionsIn PD patients with early fluctuations, three months of opicapone reduced the OFF time and improved functional outcomes, suggesting potential benefits in the early stages.

Related topics